Skip to main content

Table 4 OCT -derived study endpoints

From: Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography

  Standard of care
(N = 31)
Alirocumab
(N = 30)
P Value
Minimum fibrous cap thickness, um
 Baseline 116.4 (90.1 to 136.2) 126.0 (87.5 to 145.5) 0.44
 After 36 weeks treatment 124.2 (98.2 to 144.3) 144.0 (111.5 to 151.8) 0.049
 Changes from baseline 13.2 (7.4 to 18.6) 18.0 (10.8 to 29.2) 0.029
Maximum lipid arc, degree
 Baseline 110.9 (90.2 to 132.4) 109.6 (89.8 to 130.0) 0.53
 After 36 weeks treatment 102.2 (87.0 to 123.1) 93.5 (77.5 to 108.1) 0.19
 Changes from baseline −8.4 (−2.0 to −10.5) −15.1 (−7.8 to − 24.5) 0.008
Minimum lumen area, mm2
 Baseline 2.47 (2.20 to 2.74) 2.32 (2.07 to 2.63) 0.22
 After 36 weeks treatment 2.60 (2.19 to 2.90) 2.57 (2.27 to 2.90) 0.77
 Changes from baseline 0.13 (0.12 to 0.24) 0.20 (0.10 to 0.33) 0.006
TCFA, %(n)
 Baseline 25.8 (8) 20.0 (6) 0.59
 After 36 weeks treatment 16.1 (5) 3.3 (1) 0.09
  1. TCFA thin-cap fibroatheroma